Table 1.
Demographics and baseline characteristics of white CAMP participants (N=604) in the three treatment arms.
| Characteristics | Placebo (N=250) |
Budesonide (N=175) |
Nedocromil (N=179) |
|
|---|---|---|---|---|
| Age, years (SD) | 8.8 (2.2) | 8.8 (2.1) | 9.0 (2.2) | |
| Height, cm (SD) | 132.8 (14.1) | 133.1 (13.5) | 134.1 (13.9) | |
| Female, N (%) | 107 (42.8) | 76 (43.4) | 57 (31.8) | |
| Asthma Severity N (%) | Mild | 127 (50.8) | 78 (44.6) | 87 (48.6) |
| Moderate | 123 (49.2) | 97 (55.4) | 92 (51.4) | |
| Coughing/wheezing at baseline (SD) | 4.9 (1.1) | 5.0 (1.1) | 4.9 (1.1) | |
| FVC before bronchodilator use (% of predicted) | 105.3 (12.7) | 105.4 (13.7) | 103.1 (12.9) | |
| FVC after bronchodilator use (% of predicted) | 107.1 (12.1) | 108.2 (13.6) | 105.6 (12.3) | |